Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Updates from the CharisMMa study

Enrique Ocio • 14 May 2022
COMy 2022
Multiple Myeloma
CharisMMA

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, briefly discusses some results from the CharisMMa study (NCT03188536) investigating the sociodemographic characteristics of myeloma patients at relapse in Spain. Dr Ocio discusses some of the characteristics that were observed and how these may influence treatment decisions, such as employment, distance between a patient’s home and the hospital, and comorbidities. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

1:50
The recent expanded approval of cilta-cel into earlier lines of myeloma therapy
Roberto Mina • 23 Apr 2024
2:13
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy • 28 Apr 2024
History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals